Dr. Barzilai is a chaired Professor of Medicine and Genetics and the Director of the Institute for Aging Research at the Albert Einstein College of Medicine, which is currently the biggest Center in the world that studies the Biology of Aging. This Institute is the home of the Nathan Shock Center of Excellence in the Biology of Aging and the Glenn center for the Biology of Human Aging. He is the recipient of an NIH a Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of Ashkenazi Jewish centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. Dr. Barzilai is on the board of the American Federation for Aging Research, is its co-scientific director, and has served on several NIA study sections. He is also a founder of CohBar Inc., a biotech company that develops mitochondrial derived peptides as therapy for aging and its diseases. He is leading the TAME (Targeting/Taming Aging with MEtformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions.